ConductScience.org, home

Trial · NCT03248882

Results by group135

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Percent Change From Baseline in Liver Fat by Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI- PDFF) at Week 16Placebo-7.280% Confidence Interval -13.9 to 0.0Percent change
Percent Change From Baseline in Liver Fat by Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI- PDFF) at Week 16PF-05221304 2 mg-17.180% Confidence Interval -22.7 to -11.1Percent change
Percent Change From Baseline in Liver Fat by Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI- PDFF) at Week 16PF-05221304 10 mg-49.980% Confidence Interval -53.3 to -46.2Percent change
Percent Change From Baseline in Liver Fat by Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI- PDFF) at Week 16PF-05221304 25 mg-55.980% Confidence Interval -59.0 to -52.4Percent change
Percent Change From Baseline in Liver Fat by Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI- PDFF) at Week 16PF-05221304 50 mg-64.880% Confidence Interval -67.5 to -62.0Percent change
Percent Change From Baseline in Alanine Aminotransferase at Week 16Placebo-8.580% Confidence Interval -15.2 to -1.2Percent change
Percent Change From Baseline in Alanine Aminotransferase at Week 16PF-05221304 2 mg-12.580% Confidence Interval -18.7 to -5.8Percent change
Percent Change From Baseline in Alanine Aminotransferase at Week 16PF-05221304 10 mg-27.780% Confidence Interval -32.9 to -22.2Percent change
Percent Change From Baseline in Alanine Aminotransferase at Week 16PF-05221304 25 mg-31.380% Confidence Interval -36.6 to -25.5Percent change
Percent Change From Baseline in Alanine Aminotransferase at Week 16PF-05221304 50 mg-46.880% Confidence Interval -50.8 to -42.4Percent change
Number of Participants With Treatment-Emergent Adverse EventsPlaceboAll-causality AE41Participants
Number of Participants With Treatment-Emergent Adverse EventsPF-05221304 2 mgAll-causality AE40Participants
Number of Participants With Treatment-Emergent Adverse EventsPF-05221304 10 mgAll-causality AE42Participants
Number of Participants With Treatment-Emergent Adverse EventsPF-05221304 25 mgAll-causality AE45Participants
Number of Participants With Treatment-Emergent Adverse EventsPF-05221304 50 mgAll-causality AE40Participants
Number of Participants With Treatment-Emergent Adverse EventsPlaceboAll-causality SAE0Participants
Number of Participants With Treatment-Emergent Adverse EventsPF-05221304 2 mgAll-causality SAE1Participants
Number of Participants With Treatment-Emergent Adverse EventsPF-05221304 10 mgAll-causality SAE1Participants
Number of Participants With Treatment-Emergent Adverse EventsPF-05221304 25 mgAll-causality SAE2Participants
Number of Participants With Treatment-Emergent Adverse EventsPF-05221304 50 mgAll-causality SAE2Participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03248882/results